

Patient Heal Thyself.

written by InvestorNews | September 1, 2021

Many, many years ago I worked in the crude oil marketing business with a gentleman (and I use that term loosely) who had a drawer full of “marketing mints”. The so called “mints” ranged from antacids to Tylenol to Advil and various assorted other over the counter remedies for just about anything that ails you. He had a quote that I still use today, “better living through modern chemistry”. Medical science has come a long way over whatever time frame you want to compare and continues to marvel and astound with every new innovation and improvement. Society as a whole is very fortunate for all the really smart people who work hard every day to make our lives better and more comfortable.

Along those lines, today we are going to discuss a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. [XPhyto Therapeutics Corp.](#) (CSE: XPHY | OTCQB: XPHYF) is a next generation bioscience company whose business activities include: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. It’s like a health and wellness ETF all in one stock.

Similar to many of its peers in this new age of a global pandemic, XPhyto was able to adapt some of its existing IP and pivot towards the development of a rapid point of care COVID-19 RT-PCR diagnostic test. However, the key differentiator for XPhyto is that this 25-minute test is a PCR test, not your typical rapid test. The PCR test is accurate and reliable, and

has become the gold standard test for diagnosing COVID-19. In March of this year, the Company's test was [approved and registered](#) within the European Union as a commercial in vitro diagnostic test. This in turn led to [an agreement](#) with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. By the end of May, they had begun the sale of its [25-minute SARS-CoV-2 RT-PCR test system](#) in Germany. And in late June XPhyto announced that [ten COVID-19 test centers](#) in Berlin, Germany had taken delivery of approximately 1,000 tests for the summer and high travel season.

For many countries, only polymerase chain reaction (PCR) tests are accepted to travel making XPhyto's decentralized testing model critical to yield faster results and more versatile test center options. Processing will occur directly at the sample collection site representing a significant shift from conventional PCR testing models whereby samples are collected and then shipped to large centralized and automated labs for processing. So now instead of trying to track down a test facility before your flight home and hoping you get the result before you head out to the airport, all you have to do with XPhyto's test is get to the airport half an hour early and you're good to go.

This is the meat and potatoes stuff going on at XPhyto which could help achieve near term revenue and hopefully help finance the more interesting and exciting developments they have on the go. Those exciting things include the latest announcement by the Company regarding the launch of their [first biosensor test](#). This test for oral inflammation is an easy at home self-check that can be performed without the need for specific medical knowledge or training, analytical equipment or even a power supply. When placed on the tongue, the thin film dissolves and, after 5 minutes, the biosensor releases a bitter taste if oral

inflammation exists. The biosensor functions as a quick test for heightened levels of certain bacteria and viruses to check whether a doctor's visit and further tests are necessary.

In fact, this is the second biosensor announcement in a month. At the end of July, XPhyto and its [soon to be acquired](#) partner 3a-diagnostics reported the breakthrough identification of [COVID-19 biosensor](#) candidates. It's the first saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto's oral dissolvable delivery platform. These enzyme-activated biosensors are developed for real-time, low cost and easy to use oral screening applications for the rapid detection of infectious diseases at home or at the point of care. XPhyto, via 3a, has developed a pipeline of molecular biosensor screening tests for bacterial and viral infectious diseases which include stomatitis, periimplantitis, periodontitis, group A streptococcus, and influenza A. Pretty fascinating stuff, even if I don't know what half of the things they can readily identify even are.

These are just some of the activities going on at XPhyto, other pursuits include work in the psychedelic space with an exclusive development deal with a Canadian University for industrial scale synthesis of pharmaceutical grade Mescaline and an exclusive development deal with German University for industrial scale biotech production of pharmaceutical grade Psilocybin. The Company has a letter of intent for cooperation in the field of development, production, and distribution of new cannabis infused beverages and products with renowned German brewery Oettinger Brauerei GmbH. Through its wholly owned subsidiary, Vektor Pharma TF GmbH, it's planning to build a new commercial drug manufacturing facility in Germany. Hence the ETF comment earlier.

The Company should be well funded for the time being as there

were 3.1 million in the money warrants exercised for \$2.5 million prior to the July 31st expiry date. Combined with the \$1.6 million in cash available at the end of Q2 should provide enough liquidity to get to the next quarterly results which will hopefully show some revenue from the rapid COVID-19 PCR tests. The warrant exercise takes the shares outstanding to approximately 72.9 million making for a market cap of roughly \$120 million based on yesterday's close of \$1.65. Let's see if XPhyto Therapeutics provides us with a better living via their modern chemistry.

Greg Fenton on how ZEN Graphene's disease detection technology will "revolutionize the way testing is done"

written by InvestorNews | September 1, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of [ZEN Graphene Solutions Ltd.](#) (TSXV: ZEN) about ZEN's [exclusive worldwide rights](#) to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will "revolutionize the way testing is done". Affordable, easy to use, scalable and

provides results in under 10 minutes, Greg comments that this technology has the ability “to allow economies to reopen.” Tracy then asks the critical question with “will you be able to test for anything?”

To find out – watch the full interview, [click here](#)

About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing **ZEN Guard™**, a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN’s Albany Pure™ Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company”

being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

Sixth Wave's revolutionary gold processing technology, now enters the lithium extraction race

written by InvestorNews | September 1, 2021

In what seems like a miracle company [Sixth Wave Innovations Inc.](#) (CSE: SIXW | OTCQB: ATURF) ("Sixth Wave") has the technology to detect and/or extract any number of substances as widespread as SARS-CoV-2 (the virus that causes COVID-19), cannabinoids, gold or lithium. The applications for this technology are potentially enormous.

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs).

Sixth Wave's MIPs can detect COVID-19

On April 14 Sixth Wave [announced](#) that they were now able to demonstrate [colorimetric detection of SARS-CoV-2](#) utilizing Accelerated Molecularly Imprinted Polymers (AMIPs). The images below best show how it works.

The image on the left shows the AMIPs™ polymer having been exposed to SARS-CoV-2 (COVID-19) with the fluorescent highlights indicating the presence of the virus (positive). The image on the right shows the AMIPs™ polymer having been exposed to a non-infected sample (negative)



[Source](#)

Sixth Wave MIPs are also used in cannabis extraction and processing. In April 2021 Sixth Wave [entered a Letter of Intent \(LOI\)](#) with Halucenex Life Sciences Inc. for the separation of compounds such as psilocybin, baeocystin, and others using MIPs used in Sixth Wave's Affinity™ cannabinoid purification system.

Sixth Wave's Affinity™ cannabinoid extraction technology for the cannabis industry



[Source](#): Sixth Wave Innovation website

Sixth Wave's technology gaining traction in the extraction of valuable minerals such as gold from mine tailings

On May 18 Sixth Wave [announced](#) that it has executed a non-binding LOI to test their patented IXOS® purification and extraction polymer on gold bearing tailings samples from the Barry-Hollinger Gold Mine (BHGM) in Eastern Ontario. It is estimated there are approximately 200,000 tons of tailings on the property which have been indicated to contain up to 16,000 ounces of gold. Sixth Wave will perform a combination of leaching and recovery tests, expected to start in June 2021. Sixth Wave [state](#): "The tailings test protocol could form the foundation for a business model that seeks to identify and recover gold from tailings at other mine sites in the Ontario mining district and throughout the world."

Sixth Wave's IXOS extraction technology for the gold mining industry and others



[Source](#): Sixth Wave Innovation website

Sixth Wave's technology for the extraction of lithium from geothermal brines

In April, Sixth Wave [announced](#) the acquisition of 100% of the outstanding common shares of Geolithic Corp. Sixth Wave [stated](#): "Geolithic was established in January of 2017 as a joint venture between TriLateral and Sixth Wave to exploit the latter's technology for the extraction of lithium from geothermal brines located primarily in the Salton Sea area of California. The Salton brines are renowned for their elevated levels of lithium and represent one of the largest untapped sources of lithium in the world." This move by Sixth Wave to acquire 100% of Geolithic reflects Sixth Wave's confidence in both the technology and the opportunity. With lithium demand set to surge [10-11x](#) this decade I certainly see this as a wise strategic move.

Closing remarks

Referring to their nanotechnology, Sixth Wave say they have "the smallest solutions to the world's largest problem". That certainly seems very true given their nanotechnology has proven effective at detecting COVID-19.

Whilst it is still very early stages for Sixth Wave Innovation on a market cap of just C\$33 million the potential for this small company is indeed large. If they can go on to successfully commercializing their miracle technology in either of the health or mining sectors then I would expect Sixth Wave would potentially get a whole lot bigger. Stay tuned to this very exciting company in 2021.

Sixth Wave Innovations Dr Jon Gluckman on the colorimetric detection of SARS-CoV-2

written by InvestorNews | September 1, 2021

In a recent InvestorIntel interview, Tracy Weslosky spoke with Dr. Jon Gluckman, President, CEO and Founder of [Sixth Wave Innovations Inc.](#) (CSE: SIXW | OTCQB: ATURF) about the successful demonstration of [colorimetric detection of SARS-CoV-2](#), the virus that causes COVID-19 utilizing Sixth Wave's Accelerated Molecular Imprinted Polymers ("**AMIPs**") technology.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Gluckman went on to say that colorimetric detection is a method of identifying the presence of a target substance within a test sample by means of a color reagent. He added that the Company is evaluating the detection capabilities of the technology for all the active strains of SARS-CoV-2. Dr. Gluckman also provided an update on Sixth Wave's letter of intent with Halucenex Life Sciences Inc. to explore [a collaboration](#) for the separation of compounds such as psilocybin, baeocystin, and others using molecularly imprinted polymers.

To watch the full interview, [click here](#)

About Sixth Wave Innovations Inc.

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the

process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., [click here](#)

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

A 'catch and kill' mask that offers to get us back to work, welcome SINTX

written by InvestorNews | September 1, 2021

A classic story of repurposing your tried and true Intellectual Property, allow me to introduce you to SINTX Technologies, Inc. (NASDAQ: SINT). SINTX is a leading manufacturer of silicon nitride which is a very hard, abrasion- and corrosion-resistant ceramic solid that's inherently antibacterial and antiviral. These last two factors have caused the company to create quite a stir in this new world of COVID-19.

But first, let's take a step back and look at how this company got started. Way back in 1996 the company was developing a

ceramic hip replacement system. From there they launched multiple new silicon nitride spinal implants gaining regulatory clearances in Europe, Brazil, and Australia. Today their devices are used in over 35,000 human spine implantations.

From there they diversified their product line into more industrial applications such that they are now involved in aerospace, bearings, and drilling. In October 2020 they received the AS9100D certification for the Aerospace Quality Management System, meaning that SINTX equipment now meets the stringent standards of the aerospace industry thus achieving a critical step in entering the aviation, space, and defense market sectors. Of note, they have a 30,000 sq. ft., state-of-the-art manufacturing facility (and headquarters) in Salt Lake City which is FDA registered and ISO certified.

When it comes to Silicon nitride this team and their R&D is second to none. They have over 130 peer-reviewed scientific publications, more than 85 technical and scientific presentations and 12 Patents issued with another 56 Patent applications. So when COVID-19 came along they were able to improvise and adapt to develop yet another product line to add to the mix. In October 2020 (apparently a good month for the company) the SINTX R&D team bonded silicon nitride particles consistently and evenly into the fibers of a nonwoven fabric layer, in an effort to manufacture a “catch and kill” face mask that will inactivate respiratory viruses. That’s a bit of a mouthful but essentially they found that their silicon nitride inactivated the SARS-CoV-2 virus upon contact.

And that brings us to yesterday when the company [press released](#) confirmation of results on tests done at the University of Rochester, New York, which show that fabrics containing silicon nitride had comparable efficacy against inactivation of the SARS-CoV-2 virus to what their R&D team initially discovered.

This opens up a whole new, and potentially highly profitable, business to SINTX. In addition to the “catch and kill” face mask, the Company expects the antiviral fabrics could be used in many applications, such as surgical gowns and drapes, automotive and HVAC filters, wound dressings, clothing, and more. SINTX believes that products made of its fabrics will inactivate trapped pathogens and reduce the risk of disease transmission. Effective HVAC filters would be a huge step in getting people back into offices and back on to cruise liners and into airplanes.

If you think all this is pretty interesting stuff, then you’ll really like the fact that this company has no debt, over US\$20 million in cash and ONLY 26.1 million shares outstanding on a fully diluted basis. So despite their 50+% rally in this latest news, the market cap of this intriguing company is still under US\$50 million. Granted they aren’t profitable yet, and COVID-19 negatively impacted their spinal implant business. Nevertheless, as they found one door closing it definitely opened up a new door for SINTX to show off their innovative spirit.

XPhyto Therapeutics Hugh Rogers on the fastest and most portable PCR test available

written by InvestorNews | September 1, 2021

In a recent InvestorIntel interview, Peter Clausi spoke with Hugh Rogers, CEO and Director of [XPhyto Therapeutics Corp.](#) (CSE: XPHY | OTCQB: XPHYF) about XPhyto’s rapid point-of-care COVID-19

PCR test system which is very close to commercialization.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Hugh went on to speak on the different types of COVID-19 tests out of which, he said, “PCR test is the gold standard of diagnostics.” He added that XPhyto’s PCR test is less invasive as it is oral and requires minimal equipment and training. The test has been optimized for speed and portability. “What we have designed is we believe to be the fastest and most portable PCR test available...”

To watch the full interview, [click here](#)

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

To learn more about XPhyto Therapeutics Corp., [click here](#)

Disclaimer: XPhyto Therapeutics Corp. is an advertorial member of InvestorIntel Corp.

Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio

written by InvestorNews | September 1, 2021

COVID-19 continues to be a huge global problem with global cases now over [112 million](#). Vaccines are a source of hope but just as valuable are treatments that can help infected COVID-19 patients before they become another horrific statistic.

One specialty pharmaceutical company has a potential anti-COVID-19 product currently in the clinical trial phase. That company is [Valeo Pharma Inc.](#) (CSE: VPH | OTCQB: VPHIF | FSE: VP2) ('Valeo').

Valeo has an anti-COVID-19 product currently in a clinical trial known as the Hesperidin Coronavirus Study. Valeo Pharma's Hesperco™ capsules are [Health Canada approved \(for immune support\)](#) and are at the core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial. HesperCo™ is Valeo's unique hesperidin formulation. Hesperidin is a flavonoid with powerful antioxidant properties that helps support the immune system, and may potentially help in the fight against COVID-19.

Valeo Pharma and Ingenew Pharma are trialing their Hesperco™ flavonoid product in the fight against COVID-19

Valeo [state](#)s: "Hesperidin interferes/ inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of

the virus and enable infected patients to build natural immunity. Hesperidin's safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process.....hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature....”

Note: Bold emphasis by the author.

‘Inhibiting COVID-19 entry into our cells’ and ‘boosting immunity’. Wow! This could potentially be a game-changer if successful. With the world currently at [112,654,202 confirmed COVID-19 cases](#) and [2,496,749 COVID-19 deaths](#) (as of February 24, 2021), a product that can inhibit COVID-19 while at the same time boosting our immunity would be an incredible breakthrough.

Valeo's HESPERCO™ development partner is Ingenew Pharma. Ingenew's President & CEO [stated](#): “Although hesperidin can be found in lower concentration in citrus fruits or some natural health products, a much higher hesperidin concentration, such as the one found in Hesperco™, is required to achieve therapeutic benefits...With its well-documented anti-inflammatory and anti-oxidant activity, hesperidin may also provide further protection to the infected subjects by reducing the COVID-19-induced cytokine storm (severe inflammatory response) observed in severe cases.”

Valeo Pharma is focusing on specialty products to fight neurodegenerative diseases, cancers, pain, and maybe COVID-19

About Valeo Pharma Inc.

Valeo's business plan is to become a leading Canadian-focused specialty pharmaceutical company and be the partner of choice for international companies wishing to enter the Canadian

market. Valeo's focus is mostly on specialty areas such as neurodegenerative diseases (MS, Parkinson's, and Schizophrenia), oncology (cancer) and supportive care/pain management, and hospital specialty products.

Valeo partners with pharmaceutical companies that have expertise in research & development and manufacturing while Valeo concentrates on the regulatory requirements to get a drug approved in Canada and then focuses on marketing the product. Valeo [state](#): "Our focus is getting the product on the market, and we have all the capabilities in-house to register and commercialize innovative pharmaceuticals in Canada."

Valeo currently has [10 products in their portfolio](#) with another 3 in the pipeline.

Valeo's [revenue is forecast to triple](#) from FY2020 revenue of C\$8.0 million to a forecast FY2021 revenue of C\$24.0 million.

Closing remarks

Valeo Pharma Inc. trades on a market cap of C\$68 million which seems rather small when we look at much larger pharmaceutical companies such as Pfizer Inc. on a market cap of US\$188 billion. Sure they are not comparable companies in terms of current products, revenues etc; but it does highlight the potential size to which the most successful pharmaceutical companies can grow. If we compare to the successful natural vitamin companies such as Blackmores, it trades on a market cap of A\$1.53 billion.

Valeo's strategy to partner with other product developers means they can reduce R&D expenses, time to market, and focus on marketing & sales. This is a quicker and smarter way to achieve revenues. Valeo's stock is up [128%](#) over the past year so it certainly looks like their strategy is working.

- [Valeo Pharma's Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19 \(video\)](#)
-

Valeo Pharma's Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

written by InvestorNews | September 1, 2021

In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of [Valeo Pharma Inc.](#) (CSE: VPH | OTCQB: VPHIF) about Valeo's recent [news release](#) on the use of its Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Steve went on to say "Hesperidin is a natural product with very good safety profile and potential efficacy." The Montreal Heart Institute is a leading institute that has done a number of trials. Steve commented that for them to be interested in Hesperidin is testament to the many hours of research "...demonstrating that Hesperidin could have a very positive effect on patients that are symptomatic with COVID-19."

Steve also provided an update on the commercial launch of Redesca™ which is a biosimilar used as a blood thinner. He said that the drug has "great market potential" and has recently received a [positive recommendation](#) for public reimbursement in Quebec. The company expects to launch the product in early May.

“Our revenues are slated to almost triple in the current fiscal year which ends October 21st,” Steve commented.

To watch the full interview, [click here](#)

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., [click here](#)

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

StageZero on revenues being generated via testing operations, partners and a status report on the Aristotle test

written by InvestorNews | September 1, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with

James Howard-Tripp, Chairman and CEO of [StageZero Life Sciences Ltd.](#) (TSX: SZLS) about an update on StageZero's Aristotle test. This test, which can simultaneously screen for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer, was one of numerous discussions they had in this interview.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), James went on to say that StageZero is on track and continues to advance towards the launch of its Aristotle® test. He further said that StageZero has generated revenues with its COVID-19 testing operations which continues to grow every quarter. "We think COVID revenue is going to continue for a while...it should get eclipsed by Aristotle® when Aristotle® comes forward," He said. "We are two and half time bigger now than we were in March last year."

Speaking on StageZero's Virtual COVID-19 PCR Testing Program James said, "We have partnered with [Ichor](#) and Air Canada to equip the passengers, when they leave, with kits to allow them get tested while they were away and get back again."

To watch the complete interview, [click here](#)

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomist who can prescribe and draw

samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

To know more about StageZero Life Sciences Ltd., [click here](#)

Disclaimer: StageZero Life Sciences Ltd. is an advertorial member of InvestorIntel Corp.

Fever detection system sales driving Predictiv AI's revenue higher

written by InvestorNews | September 1, 2021

This week, [Predictiv AI Inc.](#) (TSXV: PAI) reported that its channel reseller in Quebec and Atlantic Canada, [KleinCity Group](#), secured orders for Predictiv AI's ThermalPass fever-detection system from hospitals and long-term care facilities in the province of Quebec.

KleinCity expects to close more ThermalPass sales based on the high volume of inbound calls and written requests it has recorded.

Last week, Predictiv AI announced that it received 28 orders for ThermalPass units with installations scheduled before the end of year. The majority of these units were sold to a Canadian

provincial government, U.S. public schools, and several hospitals.

Michael Lende, President and CEO of Predictiv AI remarked, “We are very excited with the initial bookings as they represent verticals that are innately scalable. We are also cognizant and encouraged that these orders are formative in nature and have the potential to be significantly upsized.”

In conjunction with these recent sales and pending orders, production and assembly of ThermalPass units are ramping up, and the Company plans to expand manufacturing capacity to meet the increased demand. Predictiv AI is well funded for growth after closing a \$1.5 million financing in October.

Thermalpass to Help Food Bank Prioritize Health of its Residents

In the holiday spirit, Predictiv AI donated one of its ThermalPass fever detection systems to the [Flemingdon Food Bank](#) in Toronto, Canada.

As the demand for food banks continues to increase amid this current health crisis and busy holiday season, the ThermalPass unit will help keep patrons, staff, and volunteers, healthy and safe.

ThermalPass Fever Detection System

In May, Predictiv AI launched ThermalPass, a fever-detection system that instantly screens for higher than normal body temperatures that could be caused by influenza, pneumonia or other viruses, such as COVID-19.

ThermalPass enhances public safety by providing fast, touch-free scanning of people at entrances of high-traffic, public locations to reduce the risk of spreading COVID-19 and other fever-bearing contagions.

By integrating 24 medical-grade, non-invasive thermal sensors onto a metal frame, and taking 1200 readings per second, each unit can process 60 people per minute. Its waterproof design is flexible for both indoor and outdoor uses.

A primary factor driving the growth of this market includes increasing demand for mass screening at airports, hospitals, malls, office buildings, pharmacies, schools, stadiums and supermarkets.

Other solutions that use thermal cameras, come with privacy issues and are more expensive, costing as much as US\$15,000 compared with ThermalPass Portable (US\$6,900) or ThermalPass Pro (US\$7,300).

In addition to the upfront hardware sale of the product, Predictiv AI also books monthly recurring revenue ("MRR") from maintenance & services fees, and monetizes the aggregated data.

Global Thermal Scanners Market is a Billion Dollar Market and Growing

According to a recent report by Reportlinker, the Global Thermal Scanners Market size is expected to reach \$6.7 billion by 2025, rising at an annual growth rate of over 10%.

Even with the COVID-19 vaccines roll-out, the general public is poised to adopt new safety measures to protect society from current and future infectious diseases. For example, in the province of Ontario, under the province's Stage 3 regulations, employers are required to conduct employee screening for COVID-19 whenever an employee comes to work.

A short-term catalyst for the market was a notice in July from the US government banning Chinese-based thermal camera solutions over privacy and national security issues. These cameras need to

removed by August 2021.

Predictiv AI – Not a 1-Product Company

Based in Toronto, Canada, Predictiv AI is a strategic investor and operator of emerging technology companies with a focus on Internet of Things (“IoT”), artificial intelligence (“AI”) and Blockchain solutions.

The Company’s R&D division, AI Labs Inc., develops new products to solve real-world business problems. AI Labs jointly developed ThermalPass with Commersive Solutions, a developer of integrated, point-of-sale technologies for the retail market.

Predictiv AI’s Weather Telematics (“WTX”) subsidiary uses patented monitoring sensors to provide real-time, advanced AI-based, predictive road condition weather risk information to the insurance, logistics, fleet management and public safety sectors. In May, WTX released Alert Fleet, a weather-based software solution to enhance safety and reduce costs for the North American Fleet Management market.

Predictiv AI helps businesses and organizations make smarter decisions using AI, deep machine learning and data science.

With a market capitalization of less than \$15 million, there is still plenty of upside to this Canadian high-tech company.



[SOURCE:](#)